WO2007127839A3 - Compositions and methods for convection enhanced delivery of high molecular weight neurotherapeutics - Google Patents

Compositions and methods for convection enhanced delivery of high molecular weight neurotherapeutics Download PDF

Info

Publication number
WO2007127839A3
WO2007127839A3 PCT/US2007/067491 US2007067491W WO2007127839A3 WO 2007127839 A3 WO2007127839 A3 WO 2007127839A3 US 2007067491 W US2007067491 W US 2007067491W WO 2007127839 A3 WO2007127839 A3 WO 2007127839A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
methods
molecular weight
high molecular
enhanced delivery
Prior art date
Application number
PCT/US2007/067491
Other languages
French (fr)
Other versions
WO2007127839A2 (en
Inventor
Krystof S Bankiewicz
Sandeep Kunwar
Original Assignee
Univ California
Krystof S Bankiewicz
Sandeep Kunwar
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ California, Krystof S Bankiewicz, Sandeep Kunwar filed Critical Univ California
Priority to EP07761340A priority Critical patent/EP2023949A4/en
Priority to JP2009507951A priority patent/JP2009535360A/en
Publication of WO2007127839A2 publication Critical patent/WO2007127839A2/en
Publication of WO2007127839A3 publication Critical patent/WO2007127839A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A61K49/06—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations
    • A61K49/18—Nuclear magnetic resonance [NMR] contrast preparations; Magnetic resonance imaging [MRI] contrast preparations characterised by a special physical form, e.g. emulsions, microcapsules, liposomes
    • A61K49/1806—Suspensions, emulsions, colloids, dispersions
    • A61K49/1812—Suspensions, emulsions, colloids, dispersions liposomes, polymersomes, e.g. immunoliposomes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/10—Dispersions; Emulsions
    • A61K9/127—Liposomes
    • A61K9/1271—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers
    • A61K9/1272—Non-conventional liposomes, e.g. PEGylated liposomes, liposomes coated with polymers with substantial amounts of non-phosphatidyl, i.e. non-acylglycerophosphate, surfactants as bilayer-forming substances, e.g. cationic lipids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Dispersion Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Radiology & Medical Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

Abstract

A method of therapeutic treatment of CNS disorders using local convection enhanced delivery.
PCT/US2007/067491 2006-04-26 2007-04-26 Compositions and methods for convection enhanced delivery of high molecular weight neurotherapeutics WO2007127839A2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
EP07761340A EP2023949A4 (en) 2006-04-26 2007-04-26 Compositions and methods for convection enhanced delivery of high molecular weight neurotherapeutics
JP2009507951A JP2009535360A (en) 2006-04-26 2007-04-26 Compositions and methods for convection enhanced delivery of high molecular weight neurotherapeutic agents

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US79537106P 2006-04-26 2006-04-26
US60/795,371 2006-04-26
US90049207P 2007-02-09 2007-02-09
US60/900,492 2007-02-09

Publications (2)

Publication Number Publication Date
WO2007127839A2 WO2007127839A2 (en) 2007-11-08
WO2007127839A3 true WO2007127839A3 (en) 2008-12-11

Family

ID=38656376

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2007/067491 WO2007127839A2 (en) 2006-04-26 2007-04-26 Compositions and methods for convection enhanced delivery of high molecular weight neurotherapeutics

Country Status (4)

Country Link
US (2) US20070259031A1 (en)
EP (1) EP2023949A4 (en)
JP (1) JP2009535360A (en)
WO (1) WO2007127839A2 (en)

Families Citing this family (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AR076634A1 (en) * 2008-11-21 2011-06-29 Medgenesis Therapeutix Inc COMPOSITIONS AND METHOD TO TREAT CENTRAL NERVOUS SYSTEM DISORDERS
BRPI1007155A2 (en) * 2009-01-29 2017-05-30 Univ Of California San Francisco methods for treating a cortical neurological disorder, and for dispensing a therapeutic agent for the cortex in a primate
EP2470250A4 (en) * 2009-08-25 2013-07-17 Univ California Optimized placement of cannula for delivery of therapeutics to the brain
CN101874780B (en) * 2010-05-31 2014-01-01 沈阳药科大学 Preparation method for improving liposome entrapment efficiency
CN102357074B (en) * 2011-11-08 2013-04-24 北京中医药大学 Anti-tumor multi-medicine resistant targeted liposome
BR112015008839A2 (en) * 2012-10-19 2017-07-04 Univ California treatment of central nervous system tumors
WO2015073927A2 (en) 2013-11-15 2015-05-21 The Regents Of The University Of California Compositions, devices and methods for diagnosing heart failure and for patient-specific modeling to predict outcomes of cardiac resynchronization therapy
HUE054768T2 (en) 2014-05-02 2021-09-28 Genzyme Corp Aav vectors for retinal and cns gene therapy
EP3193871B1 (en) * 2014-08-25 2021-05-19 Nippon Kayaku Kabushiki Kaisha Ced of sn-38-loaded micelles against brain tumor
HUE057272T2 (en) 2015-02-10 2022-04-28 Genzyme Corp Enhanced delivery of viral particles to the striatum and cortex
AU2016379418A1 (en) 2015-12-22 2018-06-14 The Regents Of The University Of California Computational localization of fibrillation sources
ES2743740T3 (en) 2016-03-31 2020-02-20 Midatech Ltd Cyclodextrin-panobinostat adduct
US11013471B2 (en) 2018-04-26 2021-05-25 Vektor Medical, Inc. Display of an electromagnetic source based on a patient-specific model
WO2020010339A1 (en) * 2018-07-05 2020-01-09 The Regents Of The University Of California Computational simulations of anatomical structures and body surface electrode positioning
CN111228271A (en) * 2020-03-31 2020-06-05 青岛泱深生物医药有限公司 Lapatinib-containing pharmaceutical composition and application thereof
US20230106974A1 (en) * 2020-06-24 2023-04-06 National University Corporation Hokkaido University Agent for protection of blood brain spinal cord barrier

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260050A (en) * 1988-09-29 1993-11-09 Ranney David F Methods and compositions for magnetic resonance imaging comprising superparamagnetic ferromagnetically coupled chromium complexes
US5935795A (en) * 1991-09-20 1999-08-10 Amgen Inc. Glial cell line-derived neurotrophic factor antibody

Family Cites Families (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5077056A (en) * 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
JPH0825869B2 (en) * 1987-02-09 1996-03-13 株式会社ビタミン研究所 Antitumor agent-embedded liposome preparation
MX9203808A (en) * 1987-03-05 1992-07-01 Liposome Co Inc HIGH DRUG CONTENT FORMULATIONS: LIPID, FROM LIPOSOMIC-ANTINEOPLASTIC AGENTS.
US5004758A (en) * 1987-12-01 1991-04-02 Smithkline Beecham Corporation Water soluble camptothecin analogs useful for inhibiting the growth of animal tumor cells
US5843473A (en) * 1989-10-20 1998-12-01 Sequus Pharmaceuticals, Inc. Method of treatment of infected tissues
DE69131775T2 (en) * 1990-09-28 2000-04-20 Smithkline Beecham Corp. Process for the preparation of water-soluble camptothecin analogs, and the compounds 10-hydroxy-11-C (1-6) -alkoxycamptothecin
US5552156A (en) * 1992-10-23 1996-09-03 Ohio State University Liposomal and micellular stabilization of camptothecin drugs
AU7676894A (en) * 1993-08-27 1995-03-21 Government Of The United States Of America, As Represented By The Secretary Of The Department Of Health And Human Services, The Convection-enhanced drug delivery
FR2717824B1 (en) * 1994-03-25 1996-04-26 Rhone Poulenc Rorer Sa Recombinant viruses, preparation and use in gene therapy.
DE69527194T2 (en) * 1994-03-28 2003-02-06 Daiichi Pharmaceutical Co., Ltd. LIPOSOME CONTAINING AN X-RAY OR ULTRASONIC CONTRAST
WO1995028493A1 (en) * 1994-04-13 1995-10-26 The Rockefeller University Aav-mediated delivery of dna to cells of the nervous system
US5786344A (en) * 1994-07-05 1998-07-28 Arch Development Corporation Camptothecin drug combinations and methods with reduced side effects
US5626862A (en) * 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
US5733875A (en) * 1994-11-15 1998-03-31 Amgen Inc. Methods of using GDNF as a neuroprotective agent
US5736156A (en) * 1995-03-22 1998-04-07 The Ohio State University Liposomal anf micellular stabilization of camptothecin drugs
US5834012A (en) * 1995-05-03 1998-11-10 Roman Perez-Soler Lipid complexed topoisomerase I inhibitors
US5830857A (en) * 1995-07-14 1998-11-03 Amgen Inc. Method of treating epilepsy
US6351659B1 (en) * 1995-09-28 2002-02-26 Brainlab Med. Computersysteme Gmbh Neuro-navigation system
US5731284A (en) * 1995-09-28 1998-03-24 Amgen Inc. Method for treating Alzheimer's disease using glial line-derived neurotrophic factor (GDNF) protein product
US5741778A (en) * 1996-03-19 1998-04-21 Amgen Inc. Method for treating Huntington's disease using glial cell line-derived neurotrophic factor (GDNF) protein product
US6071533A (en) * 1996-11-12 2000-06-06 The Regents Of The University Of California Preparation of stable formulations of lipid-nucleic acid complexes for efficient in vivo delivery
US6042579A (en) * 1997-04-30 2000-03-28 Medtronic, Inc. Techniques for treating neurodegenerative disorders by infusion of nerve growth factors into the brain
JP2001517634A (en) * 1997-09-19 2001-10-09 バイオファーム ゲゼルシャフト ツア バイオテクノロジシェン エントヴィックルング ウント ツム フェルトリーブ フォン ファルマカ エムベーハー Cytokine with neurotrophic activity
US7157435B2 (en) * 1998-04-15 2007-01-02 The Regents Of The University Of California Methods for modulation of the effects of aging on the primate brain
US6815431B2 (en) * 1998-04-15 2004-11-09 Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
US6451306B1 (en) * 1998-04-15 2002-09-17 The Regents Of The University Of California Methods for therapy of neurodegenerative disease of the brain
ES2324540T3 (en) * 1998-05-27 2009-08-10 Genzyme Corporation AAV VECTORS FOR THE MANUFACTURE OF MEDICINES FOR THE ADMINISTRATION POTENTIATED BY CONVECTION.
ATE238039T1 (en) * 1998-09-16 2003-05-15 Alza Corp TOPOISOMERASE INHIBITORS ENCLOSED IN LIPOSOMES
US6420378B1 (en) * 1999-10-15 2002-07-16 Supergen, Inc. Inhibition of abnormal cell proliferation with camptothecin and combinations including the same
ES2253398T3 (en) * 2000-06-30 2006-06-01 Inex Pharmaceuticals Corp. IMPROVED LIPOSOMAL CAMPTOTECINS AND THEIR USES.
US6800281B2 (en) * 2000-11-09 2004-10-05 Oxford Biomedica (Uk) Limited Lentiviral-mediated growth factor gene therapy for neurodegenerative diseases
CA2327208A1 (en) * 2000-11-30 2002-05-30 The Government Of The United States Of America Methods of increasing distribution of therapeutic agents
US6509027B2 (en) * 2001-02-12 2003-01-21 Supergen, Inc. Injectable pharmaceutical composition comprising coated particles of camptothecin
US6497896B2 (en) * 2001-02-12 2002-12-24 Supergen, Inc. Method for administering camptothecins via injection of a pharmaceutical composition comprising microdroplets containing a camptothecin
US6534080B2 (en) * 2001-02-12 2003-03-18 Super Gen, Inc. Method for administering camptothecins via injection of pharmaceutical composition comprising coated particles of a camptothecin
US7182944B2 (en) * 2001-04-25 2007-02-27 The United States Of America As Represented By The Department Of Health And Human Services Methods of increasing distribution of nucleic acids
US6653319B1 (en) * 2001-08-10 2003-11-25 University Of Kentucky Research Foundation Pharmaceutical formulation for poorly water soluble camptothecin analogues
US6978185B2 (en) * 2001-11-09 2005-12-20 Oscor Inc. Multifilar conductor for cardiac leads
AU2003206397B2 (en) * 2002-01-04 2008-07-17 The Rockefeller University Compositions and methods for prevention and treatment of amyloid-beta peptide-related disorders
US6627614B1 (en) * 2002-06-05 2003-09-30 Super Gen, Inc. Sequential therapy comprising a 20(S)-camptothecin and an anthracycline
WO2004004644A2 (en) * 2002-07-05 2004-01-15 Beth Israel Deaconess Medical Center Combination of mtor inhibitor and a tyrosine kinase inhibitor for the treatment of neoplasms
US7158837B2 (en) * 2002-07-10 2007-01-02 Oscor Inc. Low profile cardiac leads
AU2003299140B2 (en) * 2002-09-24 2008-07-17 The Government Of The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Method for convection enhanced delivery of therapeutic agents
US8946151B2 (en) * 2003-02-24 2015-02-03 Northern Bristol N.H.S. Trust Frenchay Hospital Method of treating Parkinson's disease in humans by convection-enhanced infusion of glial cell-line derived neurotrophic factor to the putamen
US20040209810A1 (en) * 2003-02-24 2004-10-21 Gill Steven S. Method of treating Parkinson's disease in humans by intraputaminal infusion of glial cell-line derived neurotrophic factor
EP1643972A4 (en) * 2003-06-27 2010-01-20 Smithkline Beecham Corp Stabilized topotecan liposomal composition and methods
EP2338525A3 (en) * 2003-07-09 2011-08-03 California Pacific Medical Center Remote detection of substance delivery to cells
US7197361B2 (en) * 2003-08-08 2007-03-27 Oscor Inc. Cardiac lead with anodic electrode assembly having dual support hulls
DE602005018043D1 (en) * 2004-05-17 2010-01-14 Tekmira Pharmaceuticals Corp LIPOSOMAL FORMULATIONS WITH DIHYDROSPHENOMYLININ AND METHOD FOR THEIR USE
US20060095107A1 (en) * 2004-10-28 2006-05-04 Osypka Thomas P Flexible lead body for implantable stimulation leads
MX2007003850A (en) * 2004-10-05 2007-11-21 Genzyme Corp Stepped cannula.

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5260050A (en) * 1988-09-29 1993-11-09 Ranney David F Methods and compositions for magnetic resonance imaging comprising superparamagnetic ferromagnetically coupled chromium complexes
US5935795A (en) * 1991-09-20 1999-08-10 Amgen Inc. Glial cell line-derived neurotrophic factor antibody

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See also references of EP2023949A4 *

Also Published As

Publication number Publication date
EP2023949A4 (en) 2009-08-26
EP2023949A2 (en) 2009-02-18
JP2009535360A (en) 2009-10-01
US20070259031A1 (en) 2007-11-08
WO2007127839A2 (en) 2007-11-08
US20100098639A1 (en) 2010-04-22

Similar Documents

Publication Publication Date Title
WO2007127839A3 (en) Compositions and methods for convection enhanced delivery of high molecular weight neurotherapeutics
WO2007051062A3 (en) Substituted dihydropyridines and methods of use
EP2059282A4 (en) Apparatus, methods and devices for treatment of ocular disorders
EP2007398A4 (en) High delivery rates for lipid based drug formulations, and methods of treatment thereof
LT2374472T (en) Compositions and methods for treating ophthalmic disorders
GB0818413D0 (en) CD47 Related compositions and methods for treating immunological diseases and disorders
WO2008027542A3 (en) 5-substituted isoindoline compounds
SI2019683T1 (en) Administration of growth factors for the treatment of cns disorders
WO2007111994A3 (en) Compounds and methods for treatment of disorders associated with er stress
WO2008024439A3 (en) 4-aminoquinazoline derivatives and methods of use thereof
EP2110988A4 (en) Method, adjustment mechanism and system for improving stability of lines
WO2008076754A3 (en) Compounds and compositions as inhibitors of cannabinoid receptor 1 activity
WO2008030367A3 (en) Selective myostatin inhibitors
WO2007050793A3 (en) Methods and compositions for the treatment of marfan syndrome and associated disorders
GB2466912B (en) Compositions and methods for treating lysosomal disorders
WO2007106537A3 (en) Aminoquinolones as gsk-3 inhibitors
EP2012807A4 (en) Pharmaceutical composition of enterosorbent and prebiotics, dosage forms, and the method for prevention and treatment of gastrointestinal disorders
WO2009085270A3 (en) Use of inhibitors of c0nnexin43 for treatment of fibrotic conditions
WO2008073463A3 (en) Methods and compositions for treating and monitoring treatment of il-13-associated disorders
WO2007101161A8 (en) Methods and compositions for the treatment of gastrointestinal disorders
WO2008011487A3 (en) L-benzyl-l-hydr0xy-2, 3-diamin0-propyl amines and 3-benzyl-3-hydroxy-2-amino-propionicacid amides for chronic pain
PL2061501T3 (en) Method of treating respiratory disorders
WO2007140205A3 (en) Methods of treating fibrosis
IL182505A0 (en) Purified phospholipid-non-steroidal, anti-inflammatory drug associated compositions and method for preparing and using same
EP2182943A4 (en) Methods and compositions for treating fibrosis related disorders using il-17 antagonists

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 07761340

Country of ref document: EP

Kind code of ref document: A2

WWE Wipo information: entry into national phase

Ref document number: 2009507951

Country of ref document: JP

NENP Non-entry into the national phase

Ref country code: DE

REEP Request for entry into the european phase

Ref document number: 2007761340

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 2007761340

Country of ref document: EP